Workflow
减重治疗
icon
Search documents
使用司美格鲁肽减重时,吃够蛋白质有多重要!
GLP1减重宝典· 2025-09-28 11:57
Core Viewpoint - The article emphasizes the importance of adequate protein intake while using semaglutide, a GLP-1 receptor agonist, for weight loss and overall health maintenance [2][5]. Group 1: Importance of Protein Intake - Sufficient protein intake is crucial during semaglutide treatment to maintain muscle mass [2][4]. - A balanced diet including protein, vegetables, and whole grains is recommended to enhance fiber intake and reduce side effects like constipation [2][5]. Group 2: Mechanism of GLP-1 Drugs - GLP-1 receptor agonists promote insulin secretion by activating GLP-1 receptors on pancreatic beta cells, which is glucose-dependent [6]. - They inhibit glucagon secretion from pancreatic alpha cells, helping to lower blood sugar levels [6]. - GLP-1 drugs delay gastric emptying, controlling postprandial blood sugar spikes [7]. - They also regulate appetite by acting on the brain's appetite centers, aiding in food intake reduction and weight management [8]. Group 3: Metabolic Effects - Research indicates that GLP-1 drugs not only increase satiety but also directly influence metabolism [10]. - Individuals using GLP-1 analogs exhibit increased metabolic activity, leading to higher energy expenditure and potential weight loss [11][13].
颠覆减重药市场!Nature重磅发现:这种体内天然分子或将终结司美格鲁肽霸权,零副作用抑制食欲效果惊人
GLP1减重宝典· 2025-08-21 03:04
Core Insights - The article discusses groundbreaking research published in Nature that reveals the complex biological mechanisms behind obesity and weight loss, challenging traditional views of fat as merely an energy storage tissue [6][7]. Group 1: Obesity Mechanisms - Fat tissue is described as a complex "micro-society" composed of various cell types that communicate to maintain metabolic balance, rather than just a storage depot for energy [7]. - The study identifies five catastrophic changes in fat tissue during obesity: 1. An "inflammatory storm" occurs with a significant increase in immune cells, particularly lipid-associated macrophages (LAMs), leading to chronic inflammation [8]. 2. The metabolic system of fat cells becomes overloaded and dysfunctional, resulting in the accumulation of toxic byproducts [9]. 3. Cells within fat tissue exhibit signs of aging, activating senescence-associated secretory phenotype (SASP) and exacerbating inflammation and metabolic disorders [9]. 4. The microenvironment of fat tissue is altered, leading to abnormal communication between stressed fat cells and immune cells, which amplifies inflammation [9]. 5. The vascular network within fat tissue deteriorates, causing dysfunction and contributing to hypoxia and inflammation [10]. Group 2: Weight Loss and Recovery - The research highlights that weight loss leads to a remarkable transformation in fat tissue, characterized by: 1. A "metabolic super-reboot," where fat cells regain and enhance their metabolic flexibility, improving insulin sensitivity [10]. 2. A significant reduction in inflammatory immune cells, restoring immune balance in fat tissue [10]. 3. The elimination of senescent cells, which may provide new insights into anti-aging therapies [10]. 4. Restoration of normal vascular function, improving blood supply and alleviating hypoxic conditions [10]. Group 3: Implications for Obesity Treatment - The study reveals concerning findings about "obesity memory," where certain immune cells retain a "memory" of the obese state, potentially leading to rapid weight regain after weight loss [11][12]. - This suggests that successful weight loss may require interventions targeting the mechanisms of inflammation memory to achieve long-term weight management [13]. - The research indicates a shift in obesity treatment strategies from simple weight loss to more complex approaches focused on "tissue reprogramming," offering hope for billions affected by obesity [14].
重磅!Nature揭秘"零运动燃脂"密码:人工智能破译体内"食欲关停"神奇分子
GLP1减重宝典· 2025-08-16 03:04
Core Viewpoint - The article discusses a groundbreaking study by Professor Katrin Svensson's team at Stanford University, which developed an AI system called "Peptide Predictor" that discovered 2,683 previously unknown bioactive peptides, potentially revolutionizing obesity treatment [6][8]. Group 1: AI and Drug Discovery - The AI model significantly enhances drug discovery by accurately predicting which prohormone fragments may have therapeutic potential, moving from a trial-and-error approach to a more precise method [8]. - The discovery of the BRP (BRINP2-related peptide) highlights the potential of AI in identifying effective obesity treatments, showcasing its ability to select promising candidates from a vast pool [10]. Group 2: BRP's Mechanism and Benefits - BRP demonstrated remarkable appetite suppression in animal studies, showing effects comparable to popular GLP-1 drugs, indicating its strong anti-appetite activity [10]. - The peptide also optimizes metabolic regulation, enhancing fat oxidation while maintaining stable oxygen consumption and carbon dioxide production, suggesting it primarily regulates appetite rather than basal metabolic rate [12][14]. - BRP's unique mechanism of action, which activates specific neurons in the hypothalamus, avoids common side effects associated with GLP-1 drugs, such as nausea and gastrointestinal discomfort [14]. Group 3: Future Prospects - The research team has initiated preclinical safety assessments for BRP and plans to conduct the first human trials in 2026, with hopes of bringing the drug to market by 2030 [17]. - The goal is to develop a safe and effective weight loss medication that respects the body's natural metabolic balance, representing a new direction in obesity drug development [17].